Immunotherapy is the treatment that either boosts the patient's immune system or uses human-made versions of the normal parts of the immune system to kill lymphoma cells or slow their growth.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 60% of DLBCL patients are cured using standard chemotherapy, including monoclonal anti-CD20 antibody (rituximab), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, 30-40% of DLBCL patients will develop relapse or have refractory disease that cannot be cured with the standard R-CHOP therapy, indicating the need for more effective therapies for these subsets of patients. The development of rituximab was an early step in the application of immunotherapy for the 
Case presentation
A 48-year-old lady, non-smoker and non-alcoholic by habits, presented with a 1-month history of neck nodes, axillary nodes, fever, and weight loss. On examination, there was cervical, axillary and inguinal lympadenopathy, moderate splenomegaly, and moderate hepatomegaly. Her routine investigations revealed hemoglobin of 11.5gm/dl, total count of 9600/cu mm and platelet count of 326000/cu.mm. Erythrocyte sedimentation rate (ESR) was 70mm, uric acid was 6.8mg/dl, creatinine was 0.7mg/dl, potassium was 4.2mg/dl, calcium was 9.5 mg /dl, and lactate dehydrogenase was 150IU/L. Serology for human immunodeficiency virus, hepatitis B and C viruses were negative. Positron Emission Tomography-Computed Tomography scan (PET-CT) showed increased Standard Uptake Value (SUV) and hypermetabolic areas in bilateral cervical, axillary, inguinal, mediastinal, para-aortic and iliac lymph node regions, liver, spleen, and vertebral bodies. Bone marrow aspiration and trephine biopsy were not done in view of skeletal involvement. Cerebrospinal fluid analysis was normal. Histopathological examination of the cervical lymph node biopsy specimen showed B-cells with diffuse growth pattern and large lymphocytes, round in shape, pleomorphic nuclei, medium to large in size. The immunohistochemistry panel of the specimen showed positivity to B-cell antigens CD19, CD20, CD45, BCL-2 and negativity for CD3, CD5, CD10, MYC and BCL-6 and was diagnosed to have Diffuse This time, the patient was reluctant for any kind of chemotherapy. She was counselled about the new option of immunotherapeutic drug, Nivolumab. Nivolumab was administered with 3mg per kg every 2 weeks, and after 4 cycles she had a complete response which was confirmed with PET-CT. The patient tolerated immunotherapy very well without any side effects. Now, she is continuing the same dose and schedule, completed 12 th cycle last week, without any symptoms of the disease or any adverse reactions of the drug. It is planned for a total of 2 years of post-remission Nivolumab immunotherapy.
DISCUSSION
Patients with relapsed or refractory aggressive Bcell Non-Hodgkin lymphoma (B-NHL) have a poor outcome. Lymphomas were one of the first cancers to show sensitivity to manipulations of the immune 
CONCLUSION
Cancer immunotherapy that harnesses the host immune system in novel ways to kill tumor cells is emerging. Immunotherapy offers promising opportunities with the potential to induce sustained remissions and is expected to become a "game changer" for the treatment of patients with cancer. Nivolumab was well-tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B-cell lymphomas. Additional studies of Nivolumab in these diseases are ongoing.
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